The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 trial of intravesical cabazitaxel, gemcitabine, and cisplatin (CGC) for the treatment of non-muscle invasive BCG unresponsive urothelial carcinoma of the bladder.
 
Guarionex Joel DeCastro
Research Funding - Sanofi (Inst)
 
Christopher B. Anderson
No Relationships to Disclose
 
Cory Abate-Shen
No Relationships to Disclose
 
Jillian Gray
No Relationships to Disclose
 
Justin Ingram
No Relationships to Disclose
 
Mark N. Stein
Consulting or Advisory Role - Bristol-Myers Squibb/Medarex; Exelixis; Exelixis; Janssen Oncology; Merck Sharp & Dohme; Vaccitech; Xencor
Research Funding - Advaxis (Inst); AstraZeneca (Inst); Bellicum Pharmaceuticals; Bicycle Therapeutics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genocea Biosciences (Inst); Harpoon (Inst); Janssen Oncology (Inst); Lilly (Inst); Medivation/Astellas (Inst); Merck Sharp & Dohme (Inst); Nektar (Inst); Oncoceutics (Inst); Regeneron (Inst); Seagen (Inst); Suzhou Kintor Pharmaceuticals (Inst); Tmunity Therapeutics, Inc. (Inst); Xencor (Inst)
 
James M. McKiernan
No Relationships to Disclose